- In elderly patients with acute myeloid leukemia (AML), induction decitabine was associated with lower response rates vs intensive chemotherapy (IC), but delivered no significant difference in OS.
- Patients with specific cytogenetic abnormalities may be more likely to experience survival benefit with IC.
Why this matters
- Frailty and chemoresistant disease complicate the identification of elderly patients with AML who may benefit from aggressive treatment.
- Study to investigate outcomes in patients aged ≥65 years with newly diagnosed AML treated with induction decitabine (n=75) or IC (n=32).
- Median age at diagnosis, 71 (range, 65-81) years.
- 33 patients had poor-risk cytogenetics.
- Funding: National Research Foundation of Korea; Asan Institute for Life Sciences, Korea.
- 65.6% overall response rate (ORR) with IC vs 26.1% with decitabine (P<.001>
- 65.6% complete remission (CR) with IC vs 13.0% with decitabine (P<.001>
- 14.8 months median OS with IC vs 11.0 months with decitabine (P=.124).
- In patients harboring FLT3-ITD mutation, IC was associated with higher CR (P=.005) and longer OS (P=.025).
- In patients with poor-risk cytogenetics other than –7del(7q), IC was associated with higher CR (P=.001), longer OS (P=.005), and longer event-free survival (P=.011).
- Limited sample size.